An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease

AbstractIntroduction: Alzheimer’s disease (AD) is the most common cause of major neurocognitive disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden projected...